Date: 2014-09-17
Type of information: Licensing agreement
Compound: antibody drug conjugates
Company: Merck Serono, a Merck KGaA company (Germany) Sutro Biopharma (USA - CA)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism:
Disease:
Details: * On September 17, 2014, Merck Serono and Sutro Biopharma announced a collaboration and license agreement to develop antibody drug conjugates (ADCs). The collaboration will allow Merck Serono to take advantage of Sutro’s technology platforms in its oncology programs to develop ADCs for multiple undisclosed targets. Under the terms of the agreement, Sutro and Merck Serono will collaborate to discover and develop multiple ADCs utilizing Sutro’s cell-free protein synthesis platforms, Xpress CF™ and Xpress CF+™. Sutro will be responsible for delivering ADCs for Phase I clinical trials. Merck Serono will be responsible for clinical development and commercialization of any resulting products.
Financial terms: Merck Serono will make an upfront payment to Sutro and will fund certain R&D activities. Sutro is also eligible to receive payments on completion of certain research, development and regulatory milestones potentially totaling approximately € 230 million as well as royalties on product sales. Further financial details are not being disclosed.
Latest news:
